A 57-year-old womanwas admitted with symmetrical proximal muscle weakness, liver dysfunction, abnormal muscle enzymes, and she was an antibody to hepatitis B e (anti-HBe) positive hepatitis B virus (HBV) carrier. Biopsy of her left quadriceps femoris showed myositis, so prednisolone was started at 40 mg/day. However,her hepatic function deteriorated and liver biopsy after 4 months showed acute hepatitis with partial submassive necrosis. Treatment with interferonalpha and cyclosporin A progressively reduced the transaminase and HBV-DNAlevels. Early treatment with interferon-alpha plus cyclosporin A can control exacerbation of hepatitis B.
Introduction
The withdrawal of chemotherapy for malignancy in hepatitis B virus (HBV) carriers may result in acute hepatic failure due to the destruction of hepatocytes as a result of the sudden increase in viral replication (1, 2). In addition, corticosteroid therapy for chronic active hepatitis B, nephrotic syndrome, or bullous pemphigoid has occasionally caused hepatic failure by promoting reactivation of . During the tapering of prednisolone therapy for polymyositis, we encountered exacerbation of hepatitis B in a HBV carrier with antibody to hepatitis B e antigen (anti-HBe). Because this patient responded well to therapy with interferon-alpha and cyclosporin A, neither acute hepatic failure nor liver cirrhosis developed.
Case Report
A 57-year-old woman was admitted to hospital on August 23, 1996. Examination revealed symmetrical proximal muscle weakness with a score of4/5 on manual muscle testing, but no neurological sign or muscle atrophy was observed. Laboratory tests showed myositis and revealed that she was an anti-HBe positive HBV carrier (Table 1) . Liverbiopsy and muscle biopsy (left quadriceps femoris) were performed. Liver biopsy showed no evidence of chronic hepatitis and only non specific reactive changes, with mild portal fibrosis and slight infiltration of inflammatory cells. Staining for hepatitis B core antigen (HBcAg) was negative. Muscle biopsy revealed myositis, with inflammatory cells infiltrating the endomysium and degeneration of muscle fibers. She was diagnosed as having polymyositis complicated by HBV carrier status. From September 24, 1996, prednisolone was started at a dose of 40 mg/day. The levels ofasparate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) subsequently decreased ( Fig. 1) . However, on December 24, 1996, the HBV-DNA level was markedly increased to 450 MEq/ml. On January 13, 1997, the levels ofAST,ALT, and CK were 301 IU/Z, 715 IU//, and 111 IU//, respectively, while the levels of total bilirubin, hepaplastin test, and prothrombin time were 1.0 mg/dl, 70% and 75.6%, respectively.
Other viral markers (immunoglobulin M (IgM) class antibody to hepatitis A antigen, hepatitis C virus RNA, hepatitis D virus antibody, and hepatitis G virus RNA) were all negative. An HBV mutant (G to A at nucleotide 83 of the precore region) was detected in her serum, so acute exacerbation of hepatitis caused by this mutant was diagnosed. Humanlymphoblastoid interferon-alpha was given at a dose of6 million units (MU) daily (total dose 32 1 MU) and cyclosporin A was given at 250 mg daily (total dose 2,750 mg). On January 17, 1997, liver biopsy was repeated, revealing severe acute hepatitis with centrilobular necrosis and areas of submassive necrosis ( Fig. 2A) . Most hepatocytes were positive for HBcAg by immunohistochemical staining (Fig. 2B) . Administration of cyclosporin A wasdiscontinued on February 10 when her liver 60 ml/day 40 ml/day 100 ml/day | I l l l l l l l l l l l l l l l l l l l *~l immB Glycyrrhizin 250 mg/day f^, Cyclosporin A 6 MU/day I i l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l Interferon alpha Autoimmunity is known to be one of the causes of polymyositis. Administration of interferon can cause polymyositis ( 14), and interleukin-2 or other cytokines have something to do with the diseases (15). Cyclosporin A is an effective treatment for autoimmune hepatitis ( 1 6), and treatment with the combination of plasma exchange, interferon, and cyclosporin A is more effective than plasma exchange alone in fulminant hepatitis C ( 1 7). Therefore, we used cyclosporin A to prevent exacerbation of her polymyositis and the progression of hepatitis, because this immunosuppressive agent inhibits cytotoxic T cell activity and the production of interleukin-2
(1 8). We found that interferon-alpha plus cyclosporin A were also effective in controll ing acute exacerbation of hepatitis B.
If interferon and cyclosporin
A are administered in the early stage of viral hepatitis associated with a high risk of acute liver failure, severe hepatitis may be prevented. When managing such patients, it is important to pay attention not only to the hepatic enzyme levels but also to HBV markers and the histology of liver biopsy specimens. 373, 1990 .
